Dr. Kim on PRODIGE 37 in Pancreatic Cancer

Video

George P. Kim, MD, Orange Park Medical Center, discusses the results of the PRODIGE 37 trial in patients with pancreatic cancer.

George P. Kim, MD, Orange Park Medical Center, discusses the results of the PRODIGE 37 trial in patients with pancreatic cancer.

A recent abstract presented at the 2018 Annual ASCO Meeting looked at alternating sequences of therapy. The randomized phase II trial investigated the use of gemcitabine plus nab-paclitaxel (Abraxane) until progression. The combination was also given sequentially with 5-fluorouracil (5-FU) plus irinotecan for first-line treatment of metastatic pancreatic ductal adenocarcinoma.

The trial showed some improvement in progression-free survival, and an improvement in overall survival of 15.8 months versus 12.4 months, favoring the alternating regimen. However, Kim states that there were toxicities such as increased neutropenia and diarrhea.

Kim also states that he is not fond of using alternating regimens. Rather, he believes in using one regimen for as long as possible, taking into accounting tolerability and efficacy. First-line gemcitabine and nab-paclitaxel followed by a second-line 5-FU—based regimen, as recommended by the NCCN guidelines, is his preferred approach.

Related Videos
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Ilyas Sahin, MD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine